| |
SINGAPORE: Singapore's first commercial developer of molecular diagnostic assays or tests, Dx Assays, kicked off its operations on Monday.
The company was formed at the end of last year as a joint venture between Europe's largest biotech firm Qiagen and Bio*One Capital, a dedicated biomedical science investment firm of EDB Investments.
The new facility is located in Marsiling and the investments are estimated to involve "double-digit" millions of dollars.
The plant will develop and validate molecular diagnostic assays for biotech and pharmaceutical companies, which are used throughout all stages of drug discovery and development.
It will focus on tests for infectious diseases and oncology, with initial projects expected to be completed by the end of this year.
The 11,000 square foot facility currently houses a team of 16 staff. The number is expected to grow to 36 research & development and operations personnel in 2010.
- CNA/yb
|
